Welcome to the News Room

Pugatch Consilium unveiled at the Financial Times Latin America Healthcare & Life Sciences Summit in Sao Paulo Brazil the 2017 Biopharmaceutical Competitiveness & Investment (BCI) Latin America Special Report. This Report is derived from the main 2017 BCI Survey, a global executive opinion survey and index that measures the relative attractiveness of economies to investment from biopharmaceutical research-based companies.

Does the EU Commission really think weakening IP incentives for biopharmaceutical innovation in Europe is going to create more jobs and economic activity?

by Dr David Torstensson, Partner, Pugatch Consilium

As an industry the research-based biopharmaceutical sector is one of Europe’s biggest success stories. Companies like Novartis, Roche, Sanofi Aventis, Novo Nordisk, AstraZeneca and GSK are some of the largest, most innovative and successful research-based biopharmaceutical companies in the world. Not only do these companies have a long track record of producing ...

Pugatch Consilium has released the 2017 Biopharmaceutical Competitiveness & Investment (BCI) Survey. An executive opinion survey, in 2017 the BCI polled business leaders and local general managers from the biopharmaceutical industry about the investment environment in 31 markets. The results are available in the linked report below.

The headline results of the 2017 BCI Survey include:

The policy environment matters a great deal for biopharmaceutical investment decisions. Economies with policies supporting biopharmaceutical innovation and investment are much more likely to actually secure ...

The study (which is also available via the Social Science Research Network, SSRN) models the economic impact an SPC manufacturing and export exemption would have on the European and global research-based ...

In a world of global investment flows, securing a larger portion of the $150 billion invested per year by the research-based biopharmaceutical industry is anyone’s game. The 2017 results of the annual Biopharmaceutical Competitiveness & Investment (BCI) Survey, previewed at the International BIO Convention in San Diego in June, reveal that biopharmaceutical competitiveness turns on the policy conditions that countries decide to put in place.

A new blog post by Prof Meir Pugatch on PhRMA’s The Catalyst discusses these results and ...

Professor Meir Pugatch and Dr. David Torstensson are speaking today at the BIO international convention held in San Diego, CA. Sponsored by the Biotechnology Innovation Organization, the annual convention hosts more than 16,000 attendees from over 70 countries.

New study shows how countries can succeed in developing and building their biotech capabilities

A new study by international research consultancy Pugatch Consilium (commissioned by the Biotechnology Industry Organization) examines those national innovation strategies, policies and best practices that have been successful in creating an environment in which biotechnologies and biotechnological innovation can flourish.

2017 marks the fourth edition of the Building the Bioeconomy series of papers examining national biotechnology industrial policies. This year’s edition includes 26 countries from all major regions ...

Ma’ayan Laufer, a Senior Consultant at Pugatch Consilium, spoke last week at the III Semana de Innovación en Salud (Week of Innovation in Health) event, held at Mexico City. Ma’ayan’s presentation focused on Mexico’s performance vis-à-vis global leaders in biomedical innovation as reflected in Pugatch Consilium’s international indices – including the Building the Bioeconomy series, the International IP Index and the Biopharmaceutical Competitiveness and Investment(BCI) Index.

Professor Meir Pugatch spoke together with Tom Donohue (President and CEO of the U.S. Chamber of Commerce), David Hirschmann (President and CEO of the U.S. Chamber of Commerce Global Intellectual Property Center) and former Director of the United States Patent and Trademark Office, David Kappos, at the launch of the fifth edition of the U.S. Chamber’s International IP Index in Washington D.C earlier this week.